Literature DB >> 24130636

Laparoscopic adrenalectomy for metachronous ipsilateral metastasis following nephrectomy for renal cell carcinoma.

Petr Stránský1, Viktor Eret, Tomáš Urge, Ivan Trávníček, Zdeněk Chudáček, Ondřej Hes, Milan Hora.   

Abstract

INTRODUCTION: Although laparoscopic adrenalectomy (LA) is considered as a gold standard approach for adrenalectomy, there are minimal data describing options and outcomes of LA after previous ipsilateral nephrectomy (PIN). AIM: To describe our results in a group of patients who underwent LA after PIN.
MATERIAL AND METHODS: From August 2004 to October 2012 we performed at our institution 88 LA. Of this amount we performed 5 LA for metachronous metastasis of renal cell carcinoma (RCC) after PIN. This group was compared to a group without previous nephrectomy.
RESULTS: The group comprised 4 men (80%) and 1 woman (20%); the mean age at the time of surgery was 66.8 ±8.5 (range: 60-77) years; the mean period between nephrectomy and adrenalectomy was 5.2 (range: 1.5-14) years; the operating time was longer in patients after PIN for 7 min; the mean blood loss was higher by 22 ml; duration of hospitalization was shorter by 1.3 days, paradoxically, compared with patients without PIN. There was no need for conversion to open surgery and we did not observe any other complications.
CONCLUSIONS: Laparoscopic adrenalectomy for metastasis of RCC after PIN is a technically feasible method in selected patients and it is associated with no significant differences in perioperative data in comparison with the group without prior nephrectomy. The patients benefit from minimally invasive surgery. The performance has required an experienced laparoscopic surgeon.

Entities:  

Keywords:  adrenalectomy; kidney cancer; laparoscopy; tumour metastases

Year:  2013        PMID: 24130636      PMCID: PMC3796723          DOI: 10.5114/wiitm.2011.33813

Source DB:  PubMed          Journal:  Wideochir Inne Tech Maloinwazyjne        ISSN: 1895-4588            Impact factor:   1.195


Introduction

Surgical removal of metastases from renal cell carcinoma if it is technically possible is believed to be the best therapeutic possibility. This opinion is widely accepted although it has come only from retrospective studies. The results of individual authors’ data have significantly varied and depended on the particular constitution of an evaluated complex [1, 2]. In spite of the development of a targeted molecular therapy, the surgical therapy may be recommended to patients with metachronous adrenal meta-stases either with or in the absence of systemic therapy [1-3]. Laparoscopic adrenalectomy is considered as a gold standard of care for patients with small adrenal masses [4]. In patients who underwent previous ipsilateral partial or radical nephrectomy, laparoscopic approaches may not be considered because of obliteration of retroperitoneal landmarks, intraperitoneal adhesions and scarring at the potential operative site.

Aim

The purpose of this article is to review our experience with laparoscopic adrenalectomy for metastatic RCC (mRCC) after previous ipsilateral nephrectomy (PIN).

Material and methods

In the period from August 2004 to October 2012 we performed at our institution 88 laparoscopic adrenalectomy (LA). Five LA were performed for metachronous metastasis of renal cell carcinoma after PIN. In the same period only one open adrenalectomy was performed for extensive metastasis of renal cell carcinoma located behind the inferior vena cava and therefore it was unsuitable for laparoscopic operation (Photo 1).
Photo 1

Extensive renal cell carcinoma metastasis into the right adrenal gland, the state after transperitoneal radical nephrectomy on the right in another department 5 years ago. The patient was indicated for open adrenalectomy

Extensive renal cell carcinoma metastasis into the right adrenal gland, the state after transperitoneal radical nephrectomy on the right in another department 5 years ago. The patient was indicated for open adrenalectomy

Surgical technique

The technique of LA is well described and may be performed using a transperitoneal or retroperitoneal approach [4]. However, the retroperitoneum is obliterated in patients who have undergone nephrectomy. Therefore, a lateral transperitoneal approach is used for all the patients with PIN. After insertion of a urinary catheter, a patient is turned to the lateral flank position with elevation of the operated side. It causes medial dislocation of the bowel by gravity and avoidance of intraperitoneal adhesions. We create capnoperitoneum using a Veress needle up to pressure 12 mm Hg. We insert first a 10 mm videoport laterally from the musculus rectus abdominis for 30° optics. Subsequently we continue with revision of the abdominal cavity, and insert another 11 mm port laterally from the videoport, so that we can disrupt intraperitoneal adhesions. During preparation we use a common hook with coagulation or cutting, a harmonic scalpel or the bipolar vessel sealing system LigaSure®, Blunt tip 35 mm instrument. After dissection of adhesions we classically insert two other 5 mm ports under optical control below the ribs. In right-sided cases we use a 5 mm port under the processus xiphoideus or a 3 mm port below the ribs for liver retraction. A crucial aspect of dissection in patients undergoing LA in the setting of PIN is the liberal use of sharp dissection with endoshears. Blunt dissection can lead to injury of normal organs, dissection into incorrect tissue planes and potentially tumour violation. The liver elevation and mobilization of hepatic flexure is necessary on the right side, the mobilization of the splenic flexure and spleen on the left side. Perfect orientation in the whole operated field and identification of significant structures are highly important; it means the identification of the adrenal gland with the tumour, renal artery and vein stumps bilaterally, duodenum, vena cava inferior on the right side, tail of pancreas, splenic artery and aorta on the left side. Laparoscopic ultrasonography can help with identification of critical structures. The adrenal vein is controlled by using 5 mm polymer lockable clips Hem-o-Lok® Weck (size ML). After complete adrenal release, we insert the specimen into the plastic bag that is extracted by widening one of the ports. The scar after previous nephrectomy could be used for extraction of the specimen too. We use incision of a lateral port for abdominal cavity drainage (Photos 2–4).
Photo 2

View of the abdominal wall following laparoscopic adrenalectomy on the left. The scar after previous transperitoneal nephrectomy used for extraction of the specimen

Photo 4

Adrenal gland with metastasis of clear cell renal cell carcinoma. On the left side of the specimen, the rest of the normal adrenal gland is visible

View of the abdominal wall following laparoscopic adrenalectomy on the left. The scar after previous transperitoneal nephrectomy used for extraction of the specimen View of the abdominal wall following laparoscopic adrenalectomy on the left. The scar after previous laparoscopic nephrectomy used for extraction of the specimen Adrenal gland with metastasis of clear cell renal cell carcinoma. On the left side of the specimen, the rest of the normal adrenal gland is visible

Results

From August 2004 to October 2012 we performed 88 LA at our institution. Of this amount 5 LA were performed for metachronous metastasis of renal cell carcinoma after PIN. The group comprised 4 men (80%) and 1 woman (20%). The mean age at the time of surgery was 66.8 ±8.5 (range: 60-77 years). The mean time from nephrectomy to adrenalectomy was 5.2 (range: 1.5-14) years. Patients’ characteristics and results for each group are shown in Table I.
Table I

Patients’ characteristics and results

ParameterNo previous nephrectomy (n = 83)Previous nephrectomy (n = 5)
Age [years]58.966.8
Male324
Female511
Tumour size [cm]4.23.6
Estimated blood loss [ml]4466
Surgery time [min]8087
Length of hospitalization [days]5.94.6
Patients’ characteristics and results The mean blood loss was higher after PIN by 22 ml. The mean operating time was longer by 7 min compared with the group without previous nephrectomy. The patients after PIN were paradoxically hospitalized for a shorter period than patients without previous nephrectomy. This phenomenon was probably caused by the facts that we had no complications in this group, which would lengthen hospitalization, and the group was relatively small as well. There was no conversion in our group of patients after PIN. Results of patients undergoing LA after PIN are shown in Table II.
Table II

Results of patients undergoing laparoscopic adrenalectomy after previous ipsilateral nephrectomy

SexAge [years]Previous nephrectomy approachTNM classification and gradeTime from nephrectomy to LA [months]Time from LA to last follow-up [months]Condition at last follow-up
F60.4Open, transperitonealpT1bN0M0 G I4851Alive, sunitinib
M61.3Open, transperitonealpT1bN0M0 GI16826NED
M74.7Open, transperitonealpT1aN0M0 GII5624Alive, sunitinib
M77.5LaparoscopicpT1bN0M0 GII2411NED
M60.3LaparoscopicpT1bN0M1 GI191NED

LA – laparoscopic adrenalectomy, NED – no evidence of disease

Results of patients undergoing laparoscopic adrenalectomy after previous ipsilateral nephrectomy LA – laparoscopic adrenalectomy, NED – no evidence of disease Three patients in the PIN group achieved complete remission and have no evidence of disease, 2 patients are alive with disease and with additional targeted therapy – sunitinib (Sutent®). At the same time we also performed 7 LA for metachronous metastasis of renal cell carcinoma in the contralateral adrenal gland.

Discussion

In the classical description of a radical nephrectomy for RCC, Robson and colleagues suggested that adrenalectomy should be performed as an integral part of the surgery [5]. Modern series, however, have not shown a benefit to routinely removing the adrenal gland with radical nephrectomy. The adrenal gland may become involved by local extension, or lymphatic or haematogenous metastasis, with a 1% to 5% incidence of synchronous metastasis [6]. Ipsilateral adrenalectomy is indicated in patients with radiographic suspicion of adrenal involvement or when there is a large upper pole tumour and direct invasion of the adrenal gland is likely or when a normal adrenal gland cannot be excluded [6, 7]. Despite increased survival and improved response rates that are associated with the use of targeted therapies for mRCC, the median overall survival continues to be less than 2 years, with complete remission being seen rarely [8]. After nephrectomy, however, the time course of metastatic disease progression is variable with some patients progressing quickly while other patients slowly progress or stabilize with low volume metastasis. Patients with mRCC who are otherwise healthy and have oligometastatic disease often undergo metastasectomy because they can achieve surgical complete remission and a prolonged disease-free interval. Although several series have noted the association of surgical resection of metastases with improved survival, it is difficult to prove the survival benefit of surgery, given that these patients are highly selected. In addition, even with known prognostic factors, it is not clear which patients will benefit from metastasectomy. Published results show 51% to 88% survival in patients with intermediate and high-risk disease undergoing metastasectomy through 24 months median follow-up [9]. Adrenal metastases after ipsi- or contralateral nephrectomy are not rare [10] and adrenalectomy indicated for removal of metastases has been associated with prolonged survival [11]. In patients with adrenal metastases after nephrectomy, open adrenalectomy necessitates a large incision to gain access for removal of a small gland. In addition to the possible benefits of less pain and a quicker recovery, patients may be able to return to systemic therapy for mRCC faster when applied laparoscopic techniques are compared with open surgery. Recovery time is an important fact, because agents are frequently withheld after surgery because of concerns with wound healing while receiving therapies that target angiogenic pathways [12, 13]. Also in LA a single-port approach similar to nephrectomy can be used [14]. We have used this approach totally in 9 LA. Due to the technical difficulties, we did not use a single-port approach for LA after PIN.

Conclusions

Laparoscopic adrenalectomy for metastasis of RCC after PIN is a technically feasible method in selected patients and is associated with no significant differences in perioperative data in comparison with the group without prior nephrectomy. The laparoscopic procedure is always performed transperitoneally; considering PIN at first it is necessary to disrupt intraperitoneal adhesions. During the operation perfect orientation in already operated terrain and the identification of significant structures are very important. The surgeon who performs this procedure should be experienced in standard LA as well as reoperative open and laparoscopic surgery. The patient benefits from minimally invasive surgery and considering faster recovery it is possible to timely deploy systematic therapy for mRCC as necessary.
  11 in total

1.  Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence.

Authors:  Scott E Eggener; Ofer Yossepowitch; Joseph A Pettus; Mark E Snyder; Robert J Motzer; Paul Russo
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

2.  The results of radical nephrectomy for renal cell carcinoma.

Authors:  C J Robson; B M Churchill; W Anderson
Journal:  J Urol       Date:  1969-03       Impact factor: 7.450

3.  A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.

Authors:  Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke; Igor Frank; Eugene D Kwon; Jaime R Merchan; Michael L Blute
Journal:  J Urol       Date:  2005-11       Impact factor: 7.450

4.  Laparoscopic adrenalectomy for metachronous metastases after ipsilateral nephrectomy for renal-cell carcinoma.

Authors:  E Jason Abel; Jose A Karam; Alonso Carrasco; Surena F Matin
Journal:  J Endourol       Date:  2011-07-20       Impact factor: 2.942

5.  EAU guidelines on renal cell carcinoma: the 2010 update.

Authors:  Börje Ljungberg; Nigel C Cowan; Damian C Hanbury; Milan Hora; Markus A Kuczyk; Axel S Merseburger; Jean-Jacques Patard; Peter F A Mulders; Ioanel C Sinescu
Journal:  Eur Urol       Date:  2010-07-12       Impact factor: 20.096

6.  Resection of metastatic renal cell carcinoma.

Authors:  J P Kavolius; D P Mastorakos; C Pavlovich; P Russo; M E Burt; M S Brady
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

7.  [Laparoscopic adrenalectomy].

Authors:  P Stránský; M Hora; V Eret; J Klecka; T Urge; H Grégrová; E Dvoráková; O Hes; Z Chudácek; B Kreuzberg
Journal:  Rozhl Chir       Date:  2009-09

8.  Distant metastasis of renal adenocarcinoma in nephrectomized cases.

Authors:  H Saitoh; M Nakayama; K Nakamura; T Satoh
Journal:  J Urol       Date:  1982-06       Impact factor: 7.450

9.  Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

Authors:  Vitaly Margulis; Surena F Matin; Nizar Tannir; Pheroze Tamboli; David A Swanson; Eric Jonasch; Christopher G Wood
Journal:  J Urol       Date:  2008-05-15       Impact factor: 7.450

10.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

View more
  5 in total

1.  Retroperitoneoscopic partial adrenalectomy for metachronous renal cell carcinoma metastasis to solitary adrenal gland.

Authors:  Go Kaneko; Masahiro Katsui; Hideki Orikasa; Seiya Hattori; Satoshi Hara
Journal:  Int Cancer Conf J       Date:  2019-07-23

2.  Transoesophageal echocardiography reduces invasiveness of cavoatrial tumour thrombectomy.

Authors:  Robert Sobczyński; Tomasz Golabek; Piotr Mazur; Piotr Chłosta
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-07-28       Impact factor: 1.195

3.  Modified technique for laparoscopic running vesicourethral anastomosis.

Authors:  Tomasz Golabek; Piotr Jarecki; Jaroslaw Jaskulski; Przemyslaw Dudek; Tomasz Szopiński; Piotr Chłosta
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-06-03       Impact factor: 1.195

4.  Laparoendoscopic single-site surgery adrenalectomy - own experience and matched case-control study with standard laparoscopic adrenalectomy.

Authors:  Milan Hora; Tomáš Ürge; Petr Stránský; Ivan Trávníček; Tomáš Pitra; Kristýna Kalusová; Olga Dolejšová; Fredrik Petersson; Michal Krčma; Piotr Chlosta
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-11-12       Impact factor: 1.195

5.  A complex case of abdominal pain in a patient with pelviureteric junction obstruction.

Authors:  Przemysław Wolak; Tomasz Golabek; Mateusz Obarzanowski; Piotr Chłosta
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2014-03-20       Impact factor: 1.195

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.